Keyword: Skyrizi (risankizumab-rzaa)
Skyrizi was the first IL-23 drug for psoriasis to hit after Johnson & Johnson's Tremfya and Sun Pharma's Ilumya.
3. Michael Severino, AbbVie
The IL-23 antibody easily outperformed J&J’s Stelara and AbbVie’s own Humira, setting it up to go before regulators next year.